Immunohistochemistry Market to be driven by digital pathology adoption is expected to Grow at a CAGR of 8.00% during the forecast period 2024 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Immunohistochemistry Market” that contains information from 2019 to 2032. The Immunohistochemistry market is estimated to register a CAGR of 8.00% during the forecast period of 2024 to 2032.

Market Highlights

The global Immunohistochemistry market is accounted to register a CAGR of 8.00% during the forecast period and is estimated to reach USD 5.99 billion by 2032.

The continued trend of automation of diagnostic laboratory operations across major healthcare markets has led to an increase in the use of digital pathology systems by healthcare practitioners worldwide. In order to eliminate the need for physical slides and to facilitate the efficient collaboration of pathologists and researchers, digital immunohistochemistry (IHC) combines traditional IHC staining with digital imaging and analysis tools. This allows stained tissue slides to be converted into electronic images that can be accessed, analyzed, and stored remotely. For tissue diagnostic devices and consumables, the FDA currently has an extremely drawn-out and complicated approval process. For businesses looking to introduce novel and inventive products, this is a significant obstacle.

Key Players:

MRFR recognizes the following companies as the key players in the global Immunohistochemistry market— F. Hoffmann-LA-Roche AG (Switzerland), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), Bio-Rad Laboratories Inc. (US), Eagle Biosciences Inc. (US), Biocare Medical LLC. (US), Elabscience Biotechnology Inc. (China), Bio-Genex Laboratories (US), Diagnostic Biosystem (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals Inc. (US), Genemed Biotechnologies Inc. (US), Candoor Bioscience GMBH (Germany), Bio-Techne Corporation (US), Abcam PLC (UK), Becton, Dickinson and Company (US), Perkinelmer Inc. (US), Takara Bio, Inc. (Japan), Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Cell Signaling Technology Inc. (US), Bio SB Inc. (US), Miltenyi Biotech (Germany), Sakura finetek Japan Co., Ltd. (Japan), Enzo Biochem, Inc. (US), and Origene Technologies Inc. (US).

Segment Analysis

The global Immunohistochemistry market has been segmented based on Product, Application, and End user.

On the basis of Product, the market is segmented into Antibodies (Primary antibodies and Secondary antibodies), Reagents (Histological Stains, Blocking Sera and Reagents, Chromogenic Substrates, Fixation Reagents, Organic Solvents, Proteolytic Enzymes, Diluents, and Other Reagents), Equipment (Slide-staining Systems, Tissue Processing Systems, Slide Scanners, and Other Equipment), and Kits (IHC Kits for Human tissue, and IHC Kits for Animal tissue). The Antibodies segment was attributed to holding the largest market share in 2023. This is a result of the enormous advancements in IHC application-specific product quality, sensitivity, and specificity.

Based on Application, the global Immunohistochemistry market has been segmented into Diagnostic applications (Cancer, Infectious diseases, Autoimmune diseases, Nephrological diseases, Neurological diseases, and other diseases), Research applications (Drug development and Testing, and other research applications), and Forensic applications. The Diagnostic applications segment was expected to hold the largest market share in 2023. This is due to the increased prevalence of long-term illnesses like cancer.

Based on End user, the global Immunohistochemistry market has been segmented into Hospitals & Diagnostic Laboratories, Academic & Research Institutes, and other end users. The Hospitals & Diagnostic Laboratories segment was expected to hold the largest market share in 2023. This is because diseases like cancer, autoimmune disorders, and infectious diseases are becoming more common.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Immunohistochemistry Market Research Report

Regional Analysis

The global Immunohistochemistry market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Immunohistochemistry market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Immunohistochemistry market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Immunohistochemistry market comprises the Middle East, Africa, and Latin America.

The largest market share for Immunohistochemistry was maintained by the North American regional sector. Reputable academic institutions, research facilities, and pharmaceutical firms are frequently at the forefront of creating novel diagnostic methods and treatments, which greatly contributes to the expansion of the market in the area. The need for immunohistochemistry tests in the region is being driven by the region's growing emphasis on precision medicine, strong healthcare and research infrastructure, and leadership in medical innovation. Therefore, during the projected period, these factors are anticipated to propel market expansion in the area.

Moreover, the Europe market has been persistently growing over the forecast period. Conventional diagnostic examinations were often carried out in laboratories equipped with high-end machinery, manned by skilled individuals who were responsible for carrying out the tests within the area. Over the past few decades, there has been a gradual shift in diagnostic testing from central laboratories to testing centers that are in close proximity to patients. The necessity for automation in immunohistochemistry has arisen from the growing demand for the technique as well as a staffing scarcity in the immunology labs. Immunohistochemistry (IHC) automation offers benefits like a reduction in working time and reagent savings, as well as the chance to increase sensitivity levels, repeatability, and standardization.

Additionally, the need for immunohistochemistry techniques to be used in the healthcare industry is being driven by an increase in healthcare spending worldwide. Developing Asian nations like Vietnam, Indonesia, the Philippines, India, and others are also spending more on healthcare in an effort to enhance total health services. With the shift to value-based care, where treatment results are compensated, the healthcare sector is moving away from the fee-for-service model. The need to lower healthcare expenses is growing on a worldwide scale because medical prices are rising more quickly than economies are expanding.

Furthermore, the rest of the world's Immunohistochemistry market is divided into the Middle East, Africa, and Latin America. The market is anticipated to rise as automation in immunohistochemistry becomes more widely accepted. Conventional diagnostic procedures were often carried out in laboratories equipped with pricey machinery and manned by qualified workers who were responsible for carrying out the tests.

Key Findings of the Study

• The global Immunohistochemistry market is expected to reach USD 5.99 billion by 2032, at a CAGR of 8.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to an increase in healthcare spending worldwide,


• Based on End User, the Hospitals & Diagnostic Laboratories segment was attributed to holding the largest market in 2023.


• F Hoffmann-LA-Roche AG (Switzerland), Danaher Corporation (US), Agilent Technologies Inc. (US), Merck KGAA (Germany), Bio-Rad Laboratories Inc. (US), Eagle Biosciences Inc. (US), Biocare Medical LLC. (US), Elabscience Biotechnology Inc. (China), Bio-Genex Laboratories (US), Diagnostic Biosystem (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals Inc. (US), Genemed Biotechnologies Inc. (US), Candoor Bioscience GMBH (Germany), Bio-Techne Corporation (US), Abcam PLC (UK), Becton, Dickinson and Company (US), Perkinelmer Inc. (US), Takara Bio, Inc. (Japan), Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Cell Signaling Technology Inc. (US), Bio SB Inc. (US), Miltenyi Biotech (Germany), Sakura finetek Japan Co., Ltd. (Japan), Enzo Biochem, Inc. (US), and Origene Technologies Inc. (US) are the key market players.